migraine in kids
The
American Academy of Neurology just published 2 guidelines on migraine in kids,
one on prevention and one on treatment (see migraine pedi prevention
neuro2019 in dropbox, or doi:10.1212/WNL.0000000000008105 and
migraine
pedi treatment neuro2019 in dropbox, or doi:10.1212/WNL.0000000000008095)
---------------------
Migraine
prevention
--
15 studies on migraine prevention in children and adolescents met criteria,
from 2000-2017
--
medications:
-- topiramate: more likely than those receiving placebo to have a decrease in
the frequency of migraine or headache days, moderate confidence in the
evidence, standardized mean difference (SMD) relatively low at 0.391 (0.127 to
0.655)
-- insufficient evidence whether topiramate leads to at least a 50% reduction
in headache frequency, very low confidence in the evidence
-- divalproex:
-- insufficient evidence to determine whether children
with migraine are more or less likely to have reduction in headache frequency,
very low confidence in evidence
-- amitriptyline
-- insufficient evidence that there is a decrease in migraine frequency for
migraine related disability, very low confidence of evidence
-- propranolol
-- possibly more likely to have at least a 50% reduction in headache attacks,
low confidence in the evidence, RR 5.20 (1.59- 17.00); however, a large
effect magnitude
-- flunarizine (a calcium channel blocker, not available in the US)
-- insufficient evidence that this leads to a decrease in migraine attacks,
very low confidence in the evidence
--cinnarizine (calcium channel blocker, not available in the US):
-- probably more likely to have a reduction in headache frequency, SMD 0.83
(0.31- 1.35), significant magnitude of effect; also probably more likely to
have reduction in headache severity and possibly more likely to have at least a
50% reduction in headache
-- nimodipine
-- insufficient evidence that it decreases migraine attacks, very low
confidence in the evidence
--onabotulinumtoxinA
-- insufficient evidence of reduction in headache frequency, very low
confidence in the evidence
--
medications combined with CBT
-- children 10 to 17yo: amitriptyline with CBT was more likely to lead to a
reduction in headache frequency than amitriptyline with headache education, SMD
0.48 (0.14- 0.82), high confidence of evidence; also, at least a 50% reduction
in headache frequency (also probably more likely than those receiving
amitriptyline with headache education to have reduction in the headache-related
disability, moderate confidence in the evidence)
Recommendations:
--
clinicians should counsel patients/families of lifestyle and behavioral factors
may influence headache frequency. Migraine is associated with a family history
of migraine as well as with female sex. Potentially modifiable factors include
overweight, caffeine, alcohol, lack of physical activity, poor sleep habits,
and tobacco exposure. Depression is also associated with higher headache
disability in adolescents. Weight loss can reduce the frequency in those who
are overweight, level B recommendation
--
preventive medicines may decrease the frequency and disability of migraine, as
well as acute headache medication overuse, level B recommendation. Though there
are no data in the pediatric population (ie, this is from adults): headaches on
more than 6 days a month is a risk factor for progression to chronic migraine
as well as medication overuse for the migraines.
--
There was a pretty remarkable placebo effect in children, with 30 to 61% on
placebo having a 50% or greater reduction in headache frequency. Patients/caregivers
should understand that there was a high rate of improvement with placebo and
that the majority of preventive medications were not superior to placebo, level
B recommendation
--
clinician should discuss the potential benefit or amitriptyline combined with
CBT (amitriptyline does have an FDA black box warning regarding suicidal
thoughts and behavior in children and adolescents), topiramate, and
propranolol; and there should be shared decision-making regarding the use of
short-term treatment trials, with a minimum 2 months, all with level B
recommendation
--
For patients of childbearing potential: consider the potential teratogenic
effects of valproate and topiramate, Level A recommendation. Also, topiramate
may decrease the efficacy of oral combined hormonal contraceptives; clinician
should also recommend daily folic acid supplementation for those on topiramate
or valproate, level A recommendation
--
Children and adolescents with migraine should be screened for mood and anxiety
disorders, since they are at increased risk of headache persistence; however
high quality evidence suggests that these children are not at a greater risk of
developing recurrent headache. Clinicians should screen for mood and
anxiety disorders and management options, level B recommendation
---------------------------------------------------------------------------------------------------------------------
Migraine
Treatment
Recommendations:
--establish
a specific headache diagnosis
--diagnostic criteria for children/adolescents include: at least 5 headaches/yr
that lasted 2-72 hours if untreated (time kid sleeps can be considered part of
duration), and 2 of 4 of: pulsatile quality, unilateral, worsening with
activity or limiting activity, moderate to severe in intensity; and associated
with at least nausea, vomiting, photophobia or phonophobia
--auras
occur in 1/3 of older kids and adolescents and precede headache by 5-60 minutes
--clinicians should ask about premonitory and aura symptoms; onset, location,
quality, severity, frequency, duration, and aggravating/alleviating factors;
associated symptoms of nausea, vomiting, phonophobia and photophobia; and
pain-related disability, level B recommendation
--
acute migraine treatment
--in adults, early treatment (eg <1hr) improves pain-free rates, and likely
also in kids (level B recommendation for kids)
--many benefit from nonprescription acetaminophen, ibuprofen and naproxen
--triptans are less commonly used than in adults, with FDA prescribing
restrictions:
--almotriptan (age 12 and older)
--rizatriptan (aged 6-17)
--sumatriptan/naproxen (age 12 and older)
--zomitriptan nasal (age 12 and older).
--ergots and naproxen alone have not been studied in kids
--recommendation: trying ibuprofen first (10mg/kg), level B recommendation
--recommendation: adolescents—sumatriptan/naproxen combo (10/60, 30/180, 85/500
mg); zolmitriptan nasal spray (5mg), sumatriptan nasal spray (20mg),
rizatriptan oral dissolving tabs ( 5 or 10mg), almotriptan (6.25 or 12.5 mg),
level B recommendation
--
other medication issues:
--adult patients do respond differently to different meds; nonresponse to one
triptan does not preclude response to another (level B recommendation for kids)
--a second dose of triptan may be effective in adults who respond but the
headache recurs within 24 hours (level B recommendation for kids)
--the
same may be true for kids but daily maximum doses suggested should not be
exceeded
--nasal sumatriptan and zolmitriptan are absorbed more rapidly than oral meds
and have quicker onset of action; these may be preferred in those with
nausea/vomiting or if headache pain severity peaks quickly (level C
recommendation)
--sumatriptan/naproxen combo (10/60, 30/180, 85/500 mg) is more likely than
placebo to result in pain-free status within 2 hours
--in adolescents with incomplete response to triptan, consider offering
ibuprofen or naproxen in combo with triptan (insurance may not cover the combo
meds or may cost lots more, so may need to just add NSAID), level B
recommendation
--in
pediatric trials, the effects of meds on migraine-associated symptoms is less
pronounced than for pain. So, those with prominent nausea/vomiting should
be offered additional antiemetics as appropriate for age, level B
recommendation
--
counseling:
--counsel children/adolescents/families about lifestyle modification,
identification/minimization of migraine triggers or aggravating factors, level
B recommendation
--maintain headache diary to monitor treatment response, level B recommendation
--avoid medication overuse, level B recommendation:
--no more than 14 days of ibuprofen or
acetaminophen/month
--no more than 9 days/month of triptans or any combo of triptans and
analgesics, or more than 3 months total of opiates [they note that opiates are
included without any supportive evidence because they are included in other
migraine guidelines]
--
contraindications and precautions to triptans
--per FDA, contraindicated if history cardiovascular disease (incl stroke, TIA,
MI, severe peripheral artery dz, ischemic bowel dz, and coronary vasospasm;
cardiac accessory conduction pathway disorders.
--their
recommendation: contraindicated if history of ischemic vascular disease or
accessory conduction pathway disorders, which can be exacerbated by triptans,
level A recommendation
--
migraine with aura
--in
adults with aura, safe to take triptans during aura but may be more effective
at onset of pain, though caution is warranted in those with aura given that it
can be difficult to differentiate the aura from early stroke symptoms, esp if
the aura is non-visual one. Contraindicated by FDA in those with complex auras
(eg hemiplegic or brainstem aura), though this was based on old understanding
of migraine pathophysiology
--recommendation that adolescents can take triptan during their typical
migraine aura though may be more effective at time of pain onset, level B
recommendation)
so,
useful review. a few points:
--for
prevention:
--it is really remarkable how impressive the placebo effect is on kids
with migraine. This speaks to using the least toxic drugs available first
(and ??having a prescribable placebo??)
--there are other drugs that work pretty well in adults, including other
b-blockers than propranolol, venlafaxine, some calcium channel blockers (eg
verapamil)
--other tricyclics seem to work as well as amitryptiline
and have many fewer adverse effects. especially desipramine and nortriptyline
(though lacking rigorous studies of efficacy, these meds in clinical practice
seem to work as well for migraine, and also other indications: eg neuropathies)
--other lifestyle changes that seem to help control migraine include
regular exercise, improving sleep when that is an issue, and routine meal
schedules
for
prior blogs on placebo, see
http://gmodestmedblogs.blogspot.com/2015/04/placebo-genetics-and-placebome.html
for some general thoughts on placebos and evidence that there is a genetic
predisposition to placebo response (the “placebome” for the areas of the genome
associated with this)
http://gmodestmedblogs.blogspot.com/2016/11/benefits-of-placebo-for-low-back-pain.html
for an article on placebo effect in patients with low back pain, even when the
patient knows that they are getting a placebo!!
http://gmodestmedblogs.blogspot.com/search?q=placebo
for all of the blogs on placebos
geoff
If you would like to be on the
regular email list for upcoming blogs, please contact me at gmodest@uphams.org
to get access to all of the
blogs:
2. click on 3 parallel lines
top left, if you want to see blogs by category, then click on
"labels" and choose a category
3. or you can just click on
the magnifying glass on top right, then type in a name in the search box
and get all the blogs with that name in them
please feel free to circulate
this to others. also, if you send me their emails, i can add them to the list
Comments
Post a Comment
if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org